Trisenox arsenic trioxide: Interim Phase II results; marketed to treat refractory acute promyelocytic leukemia (APL)

CTIC said that Trisenox improved blood cell counts in 3 of 9 patients with high-risk myelodysplastic syndromes in a U.S. Phase II study of 32 patients. One of 11 evaluable low risk patients achieved a...